Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to 8.67%.

  • Journey Medical's EBIT Margin rose 111100.0% to 8.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.25%, marking a year-over-year increase of 219300.0%. This contributed to the annual value of 24.36% for FY2024, which is 217500.0% down from last year.
  • According to the latest figures from Q3 2025, Journey Medical's EBIT Margin is 8.67%, which was up 111100.0% from 19.16% recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's EBIT Margin peaked at 49.93% during Q3 2023, and registered a low of 90.02% during Q2 2021.
  • For the 5-year period, Journey Medical's EBIT Margin averaged around 31.87%, with its median value being 25.3% (2025).
  • As far as peak fluctuations go, Journey Medical's EBIT Margin tumbled by -781300bps in 2021, and later skyrocketed by 1088300bps in 2023.
  • Over the past 5 years, Journey Medical's EBIT Margin (Quarter) stood at 51.7% in 2021, then dropped by -21bps to 62.6% in 2022, then soared by 78bps to 13.79% in 2023, then skyrocketed by 219bps to 16.4% in 2024, then tumbled by -153bps to 8.67% in 2025.
  • Its last three reported values are 8.67% in Q3 2025, 19.16% for Q2 2025, and 25.3% during Q1 2025.